Oncotelic Therapeutics Opens Access to AI Platform for Biomedical Research

Oncotelic Therapeutics, Inc. has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to extract biologically meaningful signals from large and complex biomedical datasets. The platform operates without requiring training of bespoke large language models on proprietary data, potentially reducing barriers to entry for researchers working with sensitive or limited datasets. This development represents a significant step in making advanced artificial intelligence tools more accessible to the biomedical research community.

Alongside the platform access, Oncotelic is providing researchers with entry to a comprehensive TGF beta literature corpus comprising more than 125,000 PubMed abstracts through a dedicated Discord research channel. The TGF beta pathway is involved in numerous biological processes including cell growth, differentiation, and immune regulation, making this resource particularly valuable for researchers studying cancer, fibrosis, autoimmune disorders, and other conditions where this pathway plays a critical role. The platform was developed alongside Oncotelic's clinical and preclinical programs with the goal of enhancing the speed, depth, and efficiency of discovery across its pipeline.

The company, which changed its name from Mateon Therapeutics, Inc. in November 2020, is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma through OT-101 via its 45% joint venture GMP Bio, melanoma through CA4P and its wholly owned subsidiary Sapu, and Acute Myeloid Leukemia through OXi 4503. The company's acquisition of PointR Data Inc. in November 2019 was aimed at building an AI-driven biotechnology company, with PDAOAI representing a key component of this strategic direction.

Beyond oncology, Oncotelic acquired AL-101 during the fourth quarter of 2021 for intranasal delivery of apomorphine, with plans to develop it for Parkinson's Disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder. The company notes these conditions affect large populations with significant unmet treatment needs. For comprehensive information about AL-101, the company directs interested parties to its 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025, available through standard SEC channels.

The implications of opening access to PDAOAI extend beyond Oncotelic's internal research programs. By providing researchers with tools to interrogate complex biomedical evidence more efficiently, the platform could accelerate discoveries across multiple therapeutic areas. The integration of the TGF beta literature corpus offers researchers immediate access to a curated body of knowledge that would otherwise require extensive manual compilation and analysis. This approach to knowledge management and analysis represents a shift toward more collaborative, data-driven research methodologies in the biomedical field.

For the broader research community, access to such platforms could democratize advanced analytical capabilities that were previously available only to well-funded institutions or corporations. The ability to extract meaningful signals from complex datasets without training custom models on proprietary data addresses both technical and privacy concerns that often limit data sharing in biomedical research. As artificial intelligence continues to transform biomedical discovery, tools like PDAOAI may help bridge the gap between data generation and actionable insights, potentially accelerating the development of new therapies for various conditions.